News

RAMP Welcomes 5 Startups into Spring 2023 Cohort

From designing battery electric spotter tractors to developing individualized neuro-oncology treatments for aggressive gliomas, the five companies accepted into RAMP’s Spring 2023 Cohort span the gamut of technology, health science and life science innovation.

“We are thrilled to welcome these inspiring entrepreneurs and help them accelerate their vision,” said RAMP director Lisa Garcia. “Not only are these companies working in fields vital to our economic, environmental and physical health, their success and growth will enhance the technology ecosystem of western Virginia.”

  • Cairina, Inc., located in Salem, provides technologies that non-invasively measure biologic fluid flow using clinically standard imaging protocols for personalized medicine applications.
  • Code One Training Solutions, of Roanoke, offers a tech-driven, revolutionary innovation for American Heart Association CPR certification.
  • MOVA Technologies, of Pulaski, specializes in air capture technology applying sustainable, circular principles to selectively capture and harvest air contaminants as valuable byproducts that can be sold and reused.
  • SchedulerHUB, based in Roanoke, is an intuitive scheduling and analytics platform for manufacturers to manage complex production projects.
  • Trova Commercial Vehicles, Inc., located in Pulaski, develops battery electric spotter tractors (designed to move trailers and cargo containers around ports, truck terminals and distribution centers) as well as class 8 diesel to electric conversion kits.

The community is invited to “Meet the Cohort” on April 13 at the Shenandoah Club in Roanoke. At the completion of RAMP’s 12-week cohort, the entrepreneurs will present to the community at “Demo Day,” tentatively scheduled for June 8.

As part of the RAMP-in-Residence experience, startups receive $20,000 in non-equity funding, expert 1:1 mentoring, and free office space with high-speed internet in downtown Roanoke’s Gill Building. RAMP alumni also receive two years of free membership in the Roanoke-Blacksburg Technology Council; one year of membership in Virginia BIO; three years of membership in the Shenandoah Club; membership in GAN for the lifetime of the company; discounted office space following completion of the 12-week program; and three additional years of ongoing support through Exit RAMP – a suite of ever-growing and developing coaching and support services.

Founded in 2017, RAMP (Regional Accelerator and Mentoring Program) has accelerated 38 companies to date that collectively employ more than 600 people and sell products and services to all 50 U.S. states and internationally. RAMP is an affiliate of Verge, a collaborative strategic alliance that includes the Roanoke-Blacksburg Technology Council established to grow the region’s innovation economy.

 

Recent News

04/24/2024

VIPC Names Joe Benevento as President & CEO

The Board of Directors of the Virginia Innovation Partnership Corporation (VIPC) has announced that it has unanimously selected Joe Benevento as President and CEO of VIPC. Benevento has led VIPC as Interim President and CEO since September 2023 and previously served as Deputy Secretary of Commerce and Trade for the Commonwealth of Virginia since 2022.

04/23/2024

AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network

AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).  This national effort is designed to accelerate commercialization of health breakthroughs for populations that urgently need them. The Customer Experience Hub in Dallas joins Boston

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous